Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains.

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...

Moderna invested heavily in manufacturing during the pandemic to meet high demand for its Covid vaccine. The company has been reducing capacity as demand for the shot falls. Last month ...

A guide to the coronavirus vaccination rollout and what you need to know about the authorized vaccines Some 63.8% of Americans have received both doses of the two-shot Pfizer-BioNTech and Moderna ...

A coronavirus vaccine could wind up being partially effective, like the flu shot, meaning it reduces the likelihood that people who get the shot develop serious symptoms. Moderna, for instance ...

Moderna announced today (January 25) plans for testing two different booster vaccines aimed at the SARS-CoV-2 variant B.1.351, also known as 501Y.V2, that emerged in South Africa and has now spread to ...

The share price drop coincided with the approval of Moderna's vaccine to protect against new strains of COVID-19. The Centers for Disease Control (CDC) recommends an updated shot for all people ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of ...